Aurinia Announces Change to Its Board of Directors VICTORIA, British Columbia--(BUSINESS WIRE)

Announces Change to Its Board of Directors

VICTORIA, British Columbia--(BUSINESS WIRE)--March 6, 2015--Aurinia

Pharmaceuticals Inc. ("Aurinia" or the "Company") (NASDAQ:AUPH /

TSX:AUP) today announced that Mr. Kurt von Emster has tendered his

resignation as a member of the Aurinia Board of Directors, effective

March 6th, 2015. This decision is driven by Mr. von Emster's departure

from the employment of venBio LLC ("venBio"), and the retained right of

venBio to put forward a nominee of their choice for election onto the

Aurinia Board of Directors.

"The Company very much wants to thank Kurt for his contributions and

thoughtful input over the course of his tenure. We are very appreciative

of everything that Kurt has brought to us," said Dr. Richard Glickman,

Chairman of Aurinia's Board of Directors.

Aurinia is a clinical stage pharmaceutical company focused on the global

nephrology market. It is currently enrolling patients in its Phase 2b

clinical trial to evaluate the efficacy of its drug, voclosporin, as a

treatment for lupus nephritis ("LN"). LN is an inflammation of the

kidneys, that if inadequately treated can lead to end-stage renal

disease, making LN a serious and potentially life-threatening condition.

Voclosporin is a novel and potentially best in class calcineurin

inhibitor ("CNI") with extensive clinical data in over 2,600 patients in

other indications. Voclosporin is made by a modification of a single

amino acid of the cyclosporine molecule (a CNI approved for use in

transplant patients since 1983). This modification results in a more

predictable pharmacokinetic and pharmacodynamic relationship, an

increase in potency vs. cyclosporine, an altered metabolic profile, and

potential for flat dosing.

Aurinia also has development and commercialization partners in Canada,

Israel, South Africa and Greater China. Visit www.auriniapharma.com,

www.sedar.com and www.sec.gov for more information.

Aurinia Pharmaceuticals Inc.

Stephen Zaruby, 250-708-4293

& Chief Executive Officer

Michael R. Martin, 250-708-4272